BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26660520)

  • 21. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
    Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R; Song YS; Devaki T
    Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
    Primeau M; Gagnon J; Momparler RL
    Int J Cancer; 2003 Jan; 103(2):177-84. PubMed ID: 12455031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Richon V; Ni X; Talpur R; Duvic M
    J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic regulation of microRNA expression in colorectal cancer.
    Bandres E; Agirre X; Bitarte N; Ramirez N; Zarate R; Roman-Gomez J; Prosper F; Garcia-Foncillas J
    Int J Cancer; 2009 Dec; 125(11):2737-43. PubMed ID: 19521961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetics of Cutaneous T-Cell Lymphomas.
    Hara N; Sawada Y
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
    Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise A; Momparler RL
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
    Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
    Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.
    Yang Q; Tian Y; Ostler KR; Chlenski A; Guerrero LJ; Salwen HR; Godley LA; Cohn SL
    BMC Cancer; 2010 Jun; 10():286. PubMed ID: 20546602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
    Nagasawa T; Zhang Q; Raghunath PN; Wong HY; El-Salem M; Szallasi A; Marzec M; Gimotty P; Rook AH; Vonderheid EC; Odum N; Wasik MA
    Leuk Res; 2006 Mar; 30(3):303-12. PubMed ID: 16185764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
    Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
    EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.